NVS - Novartis AG
After hours:
Chart Events
Fast Stochastic
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 98.91 |
| Open | 99.85 |
| Bid | 99.34 x 1000 |
| Ask | 100.40 x 1000 |
| Day's Range | 99.18 - 99.99 |
| 52 Week Range | 74.09 - 105.56 |
| Volume | |
| Avg. Volume | 2,213,748 |
| Market Cap | 210.626B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 29.93 |
| EPS (TTM) | 3.32 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.50 (3.60%) |
| Ex-Dividend Date | Mar 09, 2023 |
| 1y Target Est | 110.75 |
Fair Value
Related Research
ZacksNovartis Announces Positive Data on Breast Cancer Drug Kisqali
Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.
ZacksOncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023.
ZacksWhy Novartis (NVS) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
ZacksNovo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros
Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.
ZacksAstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal
At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.
ZacksFDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
- Reuters
UPDATE 1-Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly. The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. The Swiss drugmaker's shares rose, even as the efficacy read-out fell short of that of a drug by Lilly, but a more favourable side effect profile might swing the balance in favour of Kisqali.
ZacksHere's Why Novartis (NVS) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Novartis (NVS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
ReutersNovartis drug cuts recurrence risk by 25% in early-stage breast cancer
Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly. The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. The results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.
GlobeNewswireNovartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1 Results were also consistent across all secondary endpoints, including distant disease-free survival and recurrence-free survival, with a trend for improved overall survival*1 The safety profile of Kisqali was favorable at 400 mg with low rates of symptomatic adv
ZacksBayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies
Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.
ZacksBristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.
ZacksAstraZeneca (AZN) Discontinues Brazikumab Development
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
ZacksZacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
GlobeNewswireSandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company
Sandoz AG to remain based in Basel, Switzerland following proposed spin-off from Novartis Announcement of planned city-center HQ marks important milestone as Sandoz prepares to become independent company Basel, as a global life sciences center, ideally located to attract top talent Basel, June 1, 2023 — Sandoz AG, a global leader in generic and biosimilar medicines, has announced the location of its future permanent headquarters in central Basel. The Sandoz AG headquarters plans to move to a lan
ZacksBristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
ZacksSanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
Zacks5 Large Drug Stocks to Watch From a Thriving Industry
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
ZacksKodiak (KOD) Advances With Tarcocimab Amid Stiff Competition
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
- Zacks
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Here is how Adma Biologics (ADMA) and Novartis (NVS) have performed compared to their sector so far this year.
- Zacks
Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
ZacksBristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
ZacksTime to Buy Stock in These Pharmaceutical Giants for EPS Growth
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
ZacksAlimera (ALIM) Completes Enrollment in Eye Disease Study
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
- GlobeNewswire
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, prevention of skeletal related complications in cancer that has spread to the bone and unresectable giant cell tumor of the bone1,2 Sandoz continues to build its biosimilars portfolio to increase patient access to high-